- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00253305
Topical Gel Anti-Fungal Agent for Tinea Unguium
Phase IIB Efficacy and Safety Study of Four Topical Gel Formulations of Anti-Fungal Agents, MQX-5858, MQX-5859, MQX-5866, and MQX-5867, Versus Vehicle in the Treatment of Tinea Unguium.
The purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis).
The formulation used as the vehicle for the active agents has been shown in earlier studies to facilitate the penetration of the active agent through fungally-infected nails. This study will examine dose-response and agent differences in terms of efficacy and safety.
Once the subject has qualified for the study, he/she will be randomly assigned to one of five study groups, dispensed appropriate study medication and instructed to apply one drop to the great toe designated for study.
Study Overview
Status
Conditions
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, United States, 85741
- Genova Clinical Research, Inc.
-
-
Florida
-
Miami Beach, Florida, United States, 33140
- Greater Miami Skin and Laser Center
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Northwest Cutaneous Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- clinical diagnosis of distal subungual tinuea unguium of one great toenail.
- between 20 - 65% infected area for target nail
- 2 mm of clear nail proximally on target nail
- positive dermatophyte culture and positive KOH test
- able to sign informed consent
- understand requirements of study
- females must be post-menopausal or agree to use approved contraceptives throughout the study
Exclusion Criteria:
- patients with nails infected with organisms other than dermatophytes
- patients with proximal subungual tinea unguium
- patients with spikes of disease extending to nail matrix
- patients with more than 5 infected nails
- patients with confounding problems/ abnormalities of target nail
- patients with screening lab values more than 20% of normal
- patients with known hypersensitivity to test material components
- patients requiring systemic medications that may interfere with study
- patients with a poor history of compliance with study requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Quanitative improvement in toenail appearance.
|
Assessment of dermatophyte culture and KOH examination.
|
Frequency and severity of adverse events.
|
Secondary Outcome Measures
Outcome Measure |
---|
Time to achieve 90% and 100% clearance of fungus from nail.
|
Assessment of treatment success.
|
Assessment of mycological success.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MQT-05-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis
-
Vésale HospitalJanssen-Cilag Ltd.CompletedPrevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of OnychomycosisBelgium
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
Janssen Korea, Ltd., KoreaCompleted
-
Cairo UniversityRecruiting
-
Mediprobe Research Inc.Emblation LimitedRecruiting
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Erchonia CorporationWithdrawnOnychomycosis of ToenailUnited States
-
William N HandelmanUnknown
-
DeviceFarm, Inc.CompletedOnychomycosis | Onychomycosis of ToenailUnited States
Clinical Trials on Organogel of naftifine, 2%
-
Genzum Life SciencesCompleted
-
Taro Pharmaceuticals USACompleted
-
Taro Pharmaceuticals USACompleted
-
Merz North America, Inc.CompletedTinea PedisUnited States
-
Merz North America, Inc.CompletedTinea CorporisUnited States, Dominican Republic, Honduras
-
Joslin Diabetes CenterSunstar, Inc.CompletedInflammation | Cardiovascular Disease | Diabetes | Insulin Resistance | Periodontal DiseaseUnited States
-
Aalborg UniversityAalborg University HospitalCompleted
-
William Beaumont HospitalsTerminatedAlzheimer's DiseaseUnited States
-
British Columbia Cancer AgencyCompletedNeuropathic Pain Secondary to Radiation TherapyCanada
-
Sinovac Research and Development Co., Ltd.Active, not recruiting